ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,629.00
0.00%
S&P ASX All Technology
3,016.30
0.00%
Brent Oil
82.765
0.00%
US Dollar vs AUD
1.51188
-0.14%
Bitcoin
63,717.84
-0.27%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. POINT Biopharma Global Inc (PNT)

  7. POINT Biopharma Global Inc (PNT) News

PNT POINT Biopharma Global Inc

12.50
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
POINT Biopharma Global Inc PNT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 12.50 10:00:00
Open Price Low Price High Price Close Price Previous Close
12.50 12.50
more quote information »

Recent News

Date Time Source Heading
08/1/202423:00EDGAR2Form 15-12G - Securities registration termination [Section..
03/1/202416:15EDGAR2Form EFFECT - Notice of Effectiveness
28/12/202309:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/12/202309:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/12/202309:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/12/202309:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/12/202309:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/12/202309:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/12/202309:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/12/202309:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/12/202301:44EDGAR2Form POS AM - Post-Effective amendments for registration..
28/12/202301:43EDGAR2Form POS AM - Post-Effective amendments for registration..
28/12/202301:42EDGAR2Form S-8 POS - Securities to be offered to employees in..
28/12/202300:54EDGAR2Form 8-K - Current report
28/12/202300:31PRNUSLilly Completes Acquisition of POINT Biopharma
19/12/202300:14EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
18/12/202323:30GLOBELantheus and POINT Biopharma Announce Positive Topline..
18/12/202322:45PRNUSLilly Extends Tender Offer to Acquire POINT Biopharma to..
05/12/202322:25IHMARKETNEWSMoody’s Reassesses China, GitLab Exceeds Estimates, Twilio..
04/12/202323:22EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
04/12/202322:45PRNUSLilly Extends Tender Offer to Acquire POINT Biopharma to..
17/11/202323:05EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
17/11/202322:45PRNUSLilly Extends Tender Offer to Acquire POINT Biopharma to..
15/11/202323:00EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
15/11/202308:33PRNUSLilly Announces the Receipt of NRC Consent in Connection..
13/11/202323:30GLOBEPOINT Biopharma Reports Third Quarter 2023 Financial Results..
13/11/202323:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202309:28EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
09/11/202308:56PRNUSLilly Announces Extension of Tender Offer to Acquire POINT..
08/11/202310:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202309:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202307:40EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
28/10/202307:20EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
13/10/202322:11EDGAR2Form SC 14D9 - Solicitation, recommendation statements
04/10/202308:24EDGAR2Form SC14D9C - Written communication relating to third party..
04/10/202301:03IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations
03/10/202322:37EDGAR2Form SC14D9C - Written communication relating to third party..
03/10/202322:35EDGAR2Form 8-K - Current report
03/10/202321:45PRNUSLilly to Acquire POINT Biopharma to Expand Oncology..
18/9/202322:00GLOBEPOINT Biopharma and Athebio Announce Partnership to Develop..
15/8/202300:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/8/202321:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202321:30GLOBEPOINT Biopharma Reports Second Quarter 2023 Financial..
14/8/202321:21EDGAR2Form 8-K - Current report
04/8/202306:05EDGAR2Form 8-K - Current report
31/7/202323:00GLOBEITM and POINT Biopharma Expand Global Supply Agreement for..
26/6/202321:45GLOBEPOINT Biopharma and AdvanCell to Collaborate in the..
26/6/202321:30GLOBEPOINT Biopharma Expands Its Research with Next-Generation..
12/6/202322:00GLOBEPOINT Biopharma Announces Appointment of Dr. Bridget Martell..
07/6/202321:00GLOBEPOINT Biopharma to Host Virtual Investor Day on Tuesday,..

Your Recent History

NASDAQ
PNT
POINT Biopharma Global
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved